Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells

Biochemical Pharmacology

Volumn 56, Issue 9, 1998, Pages 1157-1166

  Sanders, Marilyn M ^a,b   Liu, Angela A ^a   Li, Tsai Kun ^a   Wu, Hong Yan ^a   Desai, Shyamal D ^a   Mao, Yong ^a   Rubin, Eric H ^a,b   LaVoie, Edmond J ^b,c   Makhey, Darshan ^c   Liu, Leroy F ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Antineoplastic agents; Berberines; Biological transport; DNA topoisomerase poison; Selective cytotoxicity; Tumor cells, cultured

Indexed keywords

CAMPTOTHECIN; CORALYNE; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; PALMATINE; PROTOBERBERINE; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; GLIOBLASTOMA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0031772868     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00243-3     Document Type: Article

References (37)

1. Makhey D, Gatto B, Yu C, Liu A, Liu LF and LaVoie EJ, Coralyne and related compounds as inhibitors of mammalian topoisomerase I and topoisoimerase II. Bioorg Med Chem 4: 781-791, 1996.
2. Gatto B, Sanders MM, Yu C, Wu H-Y, Makhey D, LaVoie EJ and Liu LF, Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56: 2795-2800, 1996.
3. Makhey D, Gatto B, Yu C, Liu A, Liu LF and LaVoie EJ, Protoberberine alkaloids and related compounds as dual inhibitors of mammalian topoisomerase I and II. Med Chem Res 5: 1-12, 1995.
4. Suffness M and Cordell GA, Antitumor alkaloids, In: The Alkaloids (Ed. Brossi A), Vol. XXV, pp. 178-197. Academic Press, New York, 1985.
5. Bhakuni DS and Jain S, Protoberberine alkaloids. In: The Alkaloids (Ed. Brossi A), Vol. 28, pp. 95-181. Academic Press, Orlando, FL, 1986.
6. Jurayj J, Haugwitz RD, Varma RK, Paull KD, Barrett JF and Cushman M, Design and synthesis of ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro. J Med Chem 37: 2190-2197, 1994.
7. Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT and Boyd MR, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 37: 2185-2189, 1994.
8. 2-methylellipticinium acetate in human brain and non-brain tumor cell lines. Biochem Pharmacol 49: 23-32, 1995.
9. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd MR, Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
10. Noe AJ, Malapetsa A and Panasci LC, Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrinesensitive carrier system. Mol Pharmacol 44: 204-209, 1993.
11. Schimke RT, Gene amplification in cultured cells. J Biol Chem 263: 5989-5992, 1988.
12. Schimke RT, Gene amplification in cultured animal cells. Cell 37: 705-713, 1984.
13. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
14. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA and Kruh GD, Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347, 1995.
15. 2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity. Biochem Pharmacol 51: 1639-1648, 1996.
16. Vistica DT, Kenney S, Hursey ML and Boyd MR, Cellular uptake as a determinant of cytotoxicity of quaternized ellipticines to human brain tumor cells. Biochem Biophys Res Commun 200: 1762-1768, 1994.
17. Vistica DT, Kenney S, Hursey M and Boyd MR, Role of membrane potential in the accumulation of quaternized ellipticines by human tumor cell lines. J Pharmacol Exp Ther 279: 1018-1025, 1997.
18. Shero JH, Bordwell B, Rothfield NF and Earnshaw WC, High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231: 737-740, 1986.
19. Zee-Cheng K-Y and Cheng CC, Synthesis of 5,6-dihydro-6-methoxynitidine and a practical preparation of nitidine chloride. Heterocyclics 10: 85-88, 1973.
20. Gu H, Wall SC and Rudnick G, Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130, 1994.
21. Akiyama S, Fojo A, Hanover JA, Pastan I and Gottesman MM, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117-126, 1985.
22. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP and Tren JM, Pharmacological, molecular and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res 47: 5455-5460, 1987.
23. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K, Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569, 1987.
24. Mosmann T, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-63, 1983.
25. Denizot F and Lang R, Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277, 1986.
26. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski JM, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR, Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 45: 589-601, 1988.
27. Su L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR and Shoemaker RH, Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52: 3029-3034, 1992.
28. Shamma M, The Isoquinoline Alkaloids: Chemistry and Pharmacology, p. 300. Academic Press, New York, 1972.
29. Rudnick G and Clark J, From synapse to vesicle: The reuptake and storage of biogenic amine transmitters. Biochim Biophys Acta 1144: 249-263, 1993.
30. Trandelenburg U, The extraneuronal uptake and metabolism of catecholamines. In: Catecholamines I (Eds. Trandelenburg U and Weiner N), pp. 279-319. Springer, Berlin, 1988.
31. Schuldiner SA, Molecular glimpse of vesicular monoamine transporters. J Neurochem 62: 2067-2078, 1994.
32. Yelin R and Schuldiner S, The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters. FEBS Lett 377: 201-207, 1995.
33. Anderson RGW, Caveolae: Where incoming and outgoing messengers meet. Proc Nad Acad Sci USA 90: 10909-10913, 1993.
34. Smart EJ, Ying Y-s and Anderson RGW, Hormonal regulation of caveolae internalization. J Cell Biol 131: 929-938, 1995.
35. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G and Prochiantz A, Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271: 18188-18193, 1996.
36. Joliot A, Trembleau A, Raposo G, Calvet S, Volovitch M and Prochiantz A, Association of Engrailed homeoproteins with vesicles presenting caveolae-like properties. Development 124: 1865-1875, 1997.
37. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M and Koepsell H, Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372: 549-552, 1994.